Format

Send to

Choose Destination
Cancer Res Treat. 2018 Oct;50(4):1458-1461. doi: 10.4143/crt.2017.529. Epub 2018 Jan 22.

Pembrolizumab for Refractory Metastatic Myxofibrosarcoma: A Case Report.

Author information

1
Divisions of Hematology and Oncology, Department of Internal Medicine, Institute of Health Science, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju, Korea.
2
Divisions of Cardiology, Department of Internal Medicine, Institute of Health Science, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju, Korea.

Abstract

Myxofibrosarcoma is a rare tumor, refractory to cytotoxic chemotherapy and radiotherapy. Pembrolizumab is an innovative immunotherapy drug consisting of programmed death receptor ligand 1 antibody proven to be useful for numerous types of cancer cells. A patient had been diagnosed with metastatic myxofibrosarcoma, refractory to radiotherapy and conventional cytotoxic chemotherapy. The patient achieved a partial response during palliative chemotherapy with pembrolizumab for 14 cycles. To the best of our knowledge, this is the first case report demonstrating the efficacy of pembrolizumab for refractory myxofibrosarcoma.

KEYWORDS:

Immunotherapy; Pembrolizumab; Sarcoma

PMID:
29361819
PMCID:
PMC6192916
DOI:
10.4143/crt.2017.529
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Publishing M2Community Icon for PubMed Central
Loading ...
Support Center